Investors

Webcast ImageWebcast
Coherus Biosciences Inc at the Bank of America/Merrill Lynch Healthcare Conference (Replay)
05/18/17 at 8:40 a.m. PT
Coherus Biosciences Inc at the Bank of America/Merrill Lynch Healthcare Conference
Thursday, May 18, 2017 8:40 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News

DateTitle
05/16/17Coherus BioSciences Prevails in ‘135 IPR Decision
Patent Trial and Appeal Board Invalidates AbbVie U.S. Patent 8,889,135 REDWOOD CITY, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of Coherus’ petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 8,889,135 (the ‘135 Patent).  The PTAB’s decision invalidates all claims of the patent that were directed to a method for treating rh... 
05/08/17Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results
REDWOOD CITY, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reviewed corporate events and reported financial results for the quarter ended March 31, 2017. Corporate Highlights for the First Quarter 2017 Include: Immunology (anti-TNF) therapeutic franchise: CHS-1420 (adalimumab (Humira®) biosimilar candidate) Reported positive topline 24-week treatment results for CHS-1420 in patients with psoriasis. Announced filing of four petiti... 
05/01/17Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May
REDWOOD CITY, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. A fireside chat is scheduled at Deutche Bank’s 42nd Annual Health Care Conference on Wednesday, May 3rd at 10:40 a.m. EDT taking place in Boston, MA. A company presentation is scheduled at the Bank of America/Merrill Lynch Healthcare Conference on Thursday, May 18th at 8:40 a.m. PDT taking ... 
04/25/17Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
REDWOOD CITY, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), announced today that it completed the initial phases of the Biologics Price Competition and Innovation Act (BPCIA) patent exchange procedure with Amgen for Coherus’ Neulasta (pegfilgrastim) biosimilar candidate, CHS-1701.  Of the two patents originally listed by Amgen in the process, the parties have reached agreement on a single patent for potential litigation, U.S. patent 8,273,707 (the ‘707 pat... 
View All

Upcoming Events

There are currently no events scheduled.
View All

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

CHRS (Common Stock)

ExchangeNASDAQ (US Dollar)
Price$21.85
Change (%) Stock is Up 0.75 (3.55%)
Volume563,631
Data as of 05/23/17 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet